R

Ultragenyx Pharmaceutical
D

RARE

44.190
USD
0.77
(1.77%)
Market Closed
Volume
34,561
EPS
-6
Div Yield
-
P/E
-7
Market Cap
4,080,693,203
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CLRB
    -0.00200
    (-0.84%)
    0.23690 USD
    C
    CRIS
    0.03000
    (0.98%)
    3.10000 USD
    F
    FATE
    0.04000
    (2.42%)
    1.69000 USD
    K
    KRYS
    3.800
    (2.36%)
    164.660 USD
    M
    MGTX
    0.33000
    (5.65%)
    6.17000 USD
    S
    SRPT
    -0.470
    (-0.39%)
    118.970 USD
    V
    VCEL
    1.530
    (2.78%)
    56.480 USD
    V
    VCYT
    1.840
    (4.71%)
    40.900 USD
    More
News

Title: Ultragenyx Pharmaceutical

Sector: Healthcare
Industry: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.